ADAG: Adagene Corp Growth-Adjusted Market Cap to Net Income

Adagene utilizes the NEObody AI platform for automated antibody design, ensuring high margins on licensing sales. The PEG ratio demonstrates the resilience of the immuno-oncology business to economic downturns, with 0.00 serving as the current parameter value. However, the company's development is complicated by severe pressure from the Biosecure Act and US trade restrictions against the Chinese biotech sector.

This indicator serves as a key filter for identifying undervalued assets during portfolio stress testing. The metric compares the current P/E multiple with earnings growth rates, where a value below one signals potential for price appreciation. By analyzing the P/E ratio relative to expected EPS growth, an investor assesses the efficiency of the business valuation. For Adagene (ADAG), this figure reflects the market value of the prospects for monetizing oncology patents. This chart allows for an assessment of the company's discount relative to the commercialization rates of its antibodies.